Abstract
Patients with acute myeloid leukemia (AML) and a normal karyotype constitute the single largest cytogenetic group of AML. It is important to identify prognostic markers that predict patients’ outcome more precisely. The presence of mutations in FLT3 (FMS-like tyrosine kinase 3), NPM1 (Nucleophosmin), and CEBPA (CCAAT/enhancer-binding protein alpha) genes hold prognostic significance in patients with AML and normal cytogenetics. Therefore, mutation identification may help to optimize therapeutic approaches in this group of patients. Polymerase chain reaction (PCR)-based fragment length analysis for mutations in FLT3 and NPM1 has been shown to be a fast and sensitive method, while nucleotide sequencing represents a gold standard for CEBPA heterogeneous mutational screening. We describe both fragment length assay and sequencing methods for mutational analysis of these three genes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trail: the medical research council adult and children’s leukaemia working parties. Blood 92:2322–2333
Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354–365
Gulley ML, Shea TC, Fedoriw Y (2010) Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia. J Mol Diagn 12:3–16
Rau R, Brown P (2009) Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol 27:171–181
Marcucci G, Haferlach T, Dohner H (2011) Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 29(5):475–486
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, IARC, pp 120–122
Dohner H, Estey EH, Amadori S, Applebaum FR, Buchner T, Burnett AK et al (2010) Diagnosis and management of acute myeloid leukemia in adults. Recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 115:453–474
Rosnet O, Mattei M-G, Marchetto S, Birnbaum D (1991) Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Genomics 9:380–385
Turner AM, Lin NL, Issarachai S, Lyman SD, Broudy VC (1996) FLT3 receptor expression on the surface of normal and malignant hematopoietic cells. Blood 88:3383–3390
Whitman SP, Ruppert AS, Radmacher MD, Mrózek K, Paschka P, Langer C et al (2008) FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 111:1552–1559
Bacher U, Haferlach C, Schnittger S, Kern W, Kroeger N, Zander AR et al (2009) Interactive diagnostics in the indication to allogeneic SCT in AML. Bone Marrow Transplant 43:745–756
Chang JH, Olson MO (1990) Structure of the gene for rat nucleolar protein 23. J Biol Chem 265:18227–18233
Falini B, Nicoletti I, Martelli MF, Mecucci C (2007) Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc  +  AML): biologic and clinical features. Blood 109:874–885
Szankasi P, Jama M, Bahler DW (2008) A new DNA-based test for detection of nucleophosmin exon 12 mutations by capillary electrophoresis. J Mol Diagn 10:236–241
Falini B, Martelli MF, Bolli N, Bonasso R, Ghia E, Pallotta MT et al (2006) Immuohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood 108:1999–2005
Hendricks-Taylor L, Bachinski LL, Siciliano MJ, Fertitta A, Trask B, de Jone P et al (1992) The CCAAT/enhancer binding protein (C/EBP alpha) gene (CEBPA) maps to human chromosome 19q13 and related nuclear factor NF-IL6 (C/EBP beta) gene (CEBPB) maps to human chromosome 20q13.1. Genomics 14:12–17
Koschmieder S, Halmos B, Levantini E, Tenen DG (2009) Dysregulation of the C/EBPα differentiation pathway in human cancer. J Clin Oncol 27:619–628
Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fensux P et al (2008) Cooperating gene mutations in acute myeloid Leukemia: a review of the literature. Leukemia 22:915–931
Pabst T, Eyholzer M, Fos J, Mueller BU (2009) Heterogeneity within AML with CEBPA mutatons; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis. Br J Cancer 100:1343–1346
Hackanson B, Bennett KL, Brena RM, Jiang J, Claus R, Chen SS et al (2008) Epigenetic modification of CCAAT/enhancer binding protein a expression in acute myeloid leukemia. Cancer Res 68:3142–3151
Acknowledgment
The authors wish to thank Dr. Stephen Dlouhy for his review of the manuscript.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, New York
About this protocol
Cite this protocol
Zhang, Q., Bai, S., Vance, G.H. (2013). Molecular Genetic Tests for FLT3, NPM1, and CEBPA in Acute Myeloid Leukemia. In: Czader, M. (eds) Hematological Malignancies. Methods in Molecular Biology, vol 999. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-357-2_7
Download citation
DOI: https://doi.org/10.1007/978-1-62703-357-2_7
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-356-5
Online ISBN: 978-1-62703-357-2
eBook Packages: Springer Protocols